Status:

UNKNOWN

Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women

Lead Sponsor:

Gangnam Severance Hospital

Collaborating Sponsors:

Seoul National University Hospital

Severance Hospital

Conditions:

Breast Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this study is to evaluate whether trastuzumab and letrozole are effective and safe in the preoperative treatment for postmenopausal patients with hormone receptor-positive and HER2-posi...

Detailed Description

Eligibility criteria * Ages Eligible for Study: ≥ 20 years * Invasive cancer (clinical stage IB-IIIB) * Measurable tumor larger than 1cm * ECOG status 0 or 1 * Postmenopausal women * Age ≥55 years...

Eligibility Criteria

Inclusion

  • Invasive cancer (clinical stage IB-IIIC)
  • Measurable tumor larger than 1cm
  • ECOG status 0 or 1
  • Postmenopausal women
  • Age ≥55 years and amenorrhea
  • Age \<55 years and amenorrhea for ≥12 months with FSH \>30 mIU/ml
  • HER2 positive tumor
  • 3 positive on IHC
  • 2 positive on IHC with HER2 gene amplification on FISH or SISH using a single-probe or dual-probe
  • Estrogen receptor positive tumor
  • Positive ER expression with Allred score more than PS3/TS8 or modified Allred score more than PS4/TS7
  • Eligible cardiac function
  • Normal heard evaluated by ECG
  • Consider clinically non-significant arrythmia and ischemic change as normal
  • LVEF ≥ 55% measured by ECHO or MUGA scan

Exclusion

  • Inflammatory breast cancer
  • Bilateral breast cancer
  • Patients with previous breast cancer history
  • Patients with previous breast cancer treatment: Generally include hormone therapy, chemotherapy, and radiotherapy)
  • Patients having uncontrolled heart problems
  • Ischemic heart disease within 6 months
  • Congestive heart failure more than NYHA class II
  • Unstable angina
  • Clinically significant pericarditis
  • Amyloid heart disease

Key Trial Info

Start Date :

March 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 1 2019

Estimated Enrollment :

132 Patients enrolled

Trial Details

Trial ID

NCT02214004

Start Date

March 1 2015

End Date

June 1 2019

Last Update

February 15 2018

Active Locations (14)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 4 (14 locations)

1

Hallym University Sacred Heart Hospital

Anyang, South Korea

2

Inje University Pusan Paik Hospital

Busan, South Korea

3

Dankook University Hospital

Cheonan, South Korea

4

Ilsan Paik Hospital

Goyang, South Korea

Neoadjuvant Trastuzumab and Letrozole for Postmenopausal Women | DecenTrialz